
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 5.880 | 5.880 | 0.000 |
Shares | 94.430 | 94.430 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 18.467 | 22.347 |
Price to Book | 2.167 | 2.714 |
Price to Sales | 1.925 | 3.330 |
Price to Cash Flow | 14.716 | 16.400 |
Dividend Yield | 2.416 | 2.102 |
5 Years Earnings Growth | 8.128 | 6.822 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 98.820 | 97.797 |
Consumer Cyclical | 1.130 | 0.671 |
Industrials | 0.020 | 0.563 |
Technology | 0.020 | 0.380 |
Basic Materials | 0.010 | 0.472 |
Number of long holdings: 138
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Zhejiang Nhu A | CNE000001J84 | 1.19 | 21.56 | +0.28% | |
Xiamen Amoytop Biotech Co | CNE100003RT3 | 1.17 | 75.80 | -0.53% | |
Apeloa A | CNE000000Q45 | 1.12 | 13.57 | +1.12% | |
APT Medical | CNE100004C45 | 1.11 | 432.82 | -1.73% | |
Livzon Pharm A | CNE0000002Y8 | 1.10 | 34.33 | -0.32% | |
Hualan Biolog A | CNE000001JN8 | 1.08 | 16.13 | -0.19% | |
Jafron Biomedical | CNE100002995 | 1.08 | 22.40 | +0.45% | |
Raas Blood A | CNE100000C31 | 1.08 | 6.85 | 0.00% | |
Shandong Pharm | CNE000001BG9 | 1.07 | 21.94 | -0.59% | |
Beigene | CNE100005XT6 | 1.06 | 237.60 | -0.54% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
TianHong SH Exchange 300 Index Fd A | 10.04B | -1.01 | -0.23 | 1.43 | ||
TianHong ChiNext Index A | 9.8B | -1.76 | -6.56 | - | ||
TianHong ChiNext Index C | 9.8B | -1.81 | -6.74 | - | ||
TianHong CSI Food Indus Index A | 5.28B | -1.35 | -5.41 | - | ||
TianHong CSI Food Indus Index C | 5.28B | -1.40 | -5.61 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review